A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
Status:
Not yet recruiting
Trial end date:
2022-09-03
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of SHR-1314 at Week 12 in subjects with proliferation lupus
nephritis in terms of improvement of 24h UPCR, compared to placebo. The study will also
assess the safety and tolerability of SHR-1314 in the patient population over the study
period.